Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas

Intern Med. 2021 Aug 15;60(16):2607-2612. doi: 10.2169/internalmedicine.6755-20. Epub 2021 Mar 1.

Abstract

A 74-year-old woman with a cyst in her pancreatic tail was referred to our hospital. Computed tomography confirmed a large cystic lesion with irregular wall thickening, abdominal lymph node swelling, and ascites. We diagnosed her with an unresectable mucinous cystic neoplasm, since ascites cytology revealed adenocarcinoma. The patient received chemotherapy up to the fifth line for 55.2 months. Gemcitabine plus nab-paclitaxel and modified FOLFIRINOX achieved a partial response with a progression-free survival time of 12.1 and 20.4 months, respectively. The overall survival time from the beginning of first-line chemotherapy was 69.4 months.

Keywords: antineoplastic combined chemotherapy protocols; palliative therapy; pancreatic cancer; pancreatic cyst.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Aged
  • Albumins / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Humans
  • Neoplasm Metastasis
  • Paclitaxel / therapeutic use
  • Pancreas
  • Pancreatic Neoplasms* / diagnostic imaging
  • Pancreatic Neoplasms* / drug therapy
  • Progression-Free Survival

Substances

  • Albumins
  • Paclitaxel